{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:34:39Z","timestamp":1791441279764,"version":"4.3.3"},"reference-count":154,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heparan sulfate (HS) is an essential glycosaminoglycan (GAG) as a component of proteoglycans, which are present on the cell surface and in the extracellular matrix. HS-containing proteoglycans not only function as structural constituents of the basal lamina but also play versatile roles in various physiological processes, including cell signaling and organ development. Thus, inherited mutations of genes associated with the biosynthesis or degradation of HS can cause various diseases, particularly those involving the bones and central nervous system (CNS). Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders involving GAG accumulation throughout the body caused by a deficiency of GAG-degrading enzymes. GAGs are stored differently in different types of MPSs. Particularly, HS deposition is observed in patients with MPS types I, II, III, and VII, all which involve progressive neuropathy with multiple CNS system symptoms. While therapies are available for certain symptoms in some types of MPSs, significant unmet medical needs remain, such as neurocognitive impairment. This review presents recent knowledge on the pathophysiological roles of HS focusing on the pathogenesis of MPSs. We also discuss the possible use and significance of HS as a biomarker for disease severity and therapeutic response in MPSs.<\/jats:p>","DOI":"10.3390\/ijms231911724","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:39:31Z","timestamp":1665272371000},"page":"11724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-6250","authenticated-orcid":false,"given":"Kohtaro","family":"Minami","sequence":"first","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-5179","authenticated-orcid":false,"given":"Hiroki","family":"Morioka","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-0183","authenticated-orcid":false,"given":"Atsushi","family":"Imakiire","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Research Division, JCR Pharmaceuticals, Kobe 651-2241, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0008-6215(95)00166-Q","article-title":"Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin","volume":"276","author":"Griffin","year":"1995","journal-title":"Carbohydr. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1242\/jcs.03432","article-title":"Heparan sulfate proteoglycans at a glance","volume":"120","author":"Kirkpatrick","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.ircmb.2016.02.009","article-title":"Heparan Sulfate: Biosynthesis, Structure, and Function","volume":"325","author":"Li","year":"2016","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a004952","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan sulfate proteoglycans","volume":"3","author":"Sarrazin","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.matbio.2017.12.011","article-title":"The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses","volume":"71\u201372","author":"Pacifici","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mashima, R., Okuyama, T., and Ohira, M. (2022). Physiology and Pathophysiology of Heparan Sulfate in Animal Models: Its Biosynthesis and Degradation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23041963"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1242\/dev.00435","article-title":"Role of glypican 4 in the regulation of convergent extension movements during gastrulation in Xenopus laevis","volume":"130","author":"Ohkawara","year":"2003","journal-title":"Development"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","article-title":"Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling","volume":"6","author":"Capurro","year":"2005","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ydbio.2006.09.011","article-title":"The function of a Drosophila glypican does not depend entirely on heparan sulfate modification","volume":"300","author":"Kirkpatrick","year":"2006","journal-title":"Dev. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"495764","DOI":"10.1155\/2014\/495764","article-title":"Human genetic disorders and knockout mice deficient in glycosaminoglycan","volume":"2014","author":"Mizumoto","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/febs.14984","article-title":"Bone and connective tissue disorders caused by defects in glycosaminoglycan biosynthesis: A panoramic view","volume":"286","author":"Paganini","year":"2019","journal-title":"FEBS J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K","article-title":"Molecular basis of multiple exostoses: Mutations in the EXT1 and EXT2 genes","volume":"15","author":"Wuyts","year":"2000","journal-title":"Hum. Mutat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/bj2710075","article-title":"Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties","volume":"271","author":"Bielicki","year":"1990","journal-title":"Biochem. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj2590199","article-title":"Immunopurification and characterization of human alpha-L-iduronidase with the use of monoclonal antibodies","volume":"259","author":"Clements","year":"1989","journal-title":"Biochem. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/bj3040043","article-title":"Recombinant alpha-L-iduronidase: Characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts","volume":"304","author":"Unger","year":"1994","journal-title":"Biochem. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1042\/bj2340083","article-title":"Human liver sulphamate sulphohydrolase. Determinations of native protein and subunit Mr values and influence of substrate agylcone structure on catalytic properties","volume":"234","author":"Freeman","year":"1986","journal-title":"Biochem. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1042\/bj3290145","article-title":"Recombinant human sulphamidase: Expression, amplification, purification and characterization","volume":"329","author":"Bielicki","year":"1998","journal-title":"Biochem. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fan, X., Tkachyova, I., Sinha, A., Rigat, B., and Mahuran, D. (2011). Characterization of the biosynthesis, processing and kinetic mechanism of action of the enzyme deficient in mucopolysaccharidosis IIIC. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024951"},{"key":"ref_19","first-page":"523","article-title":"Human alpha-N-acetylglucosaminidase. 1. Purification and properties","volume":"80","year":"1977","journal-title":"Eur. J. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1515\/bchm2.1978.359.2.1353","article-title":"Human placenta alpha-N-acetylglucosaminidase: Purification, characterization and demonstration of multiple recognition forms","volume":"359","year":"1978","journal-title":"Hoppe Seylers Z. Physiol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bj2590209","article-title":"Human liver glucuronate 2-sulphatase. Purification, characterization and catalytic properties","volume":"259","author":"Freeman","year":"1989","journal-title":"Biochem. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/bi00596a001","article-title":"Purification and properties of beta-glucuronidase from human placenta","volume":"17","author":"Brot","year":"1978","journal-title":"Biochemistry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.199.4324.79","article-title":"Deficiencies of glucosamine-6-sulfate or galactosamine-6-sulfate sulfatases are responsible for different mucopolysaccharidoses","volume":"199","author":"Ginsberg","year":"1978","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0021-9258(17)34181-9","article-title":"N-Acetylglucosamine-6-sulfate sulfatase from human urine","volume":"254","author":"Basner","year":"1979","journal-title":"J. Biol. Chem."},{"key":"ref_25","first-page":"141","article-title":"N-acetylglucosamine 6-sulfate residues in keratan sulfate and heparan sulfate are desulfated by the same enzyme","volume":"6","author":"Hopwood","year":"1983","journal-title":"Biochem. Int."},{"key":"ref_26","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). The mucopolysaccharidoses. The Metabolic & Molecular Bases of Inherited Disease, McGraw Hill."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"165539","DOI":"10.1016\/j.bbadis.2019.165539","article-title":"Heparan sulfate proteoglycans: The sweet side of development turns sour in mucopolysaccharidoses","volume":"1865","author":"Pavone","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.1380010204","article-title":"A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype","volume":"1","author":"Scott","year":"1992","journal-title":"Hum. Mutat."},{"key":"ref_29","first-page":"102","article-title":"Mucopolysaccharidosis type I","volume":"12","author":"Wraith","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_30","unstructured":"Hashmi, M.S., and Gupta, V. (2022, May 02). Mucopolysaccharidosis Type II, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560829\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108392","DOI":"10.1016\/j.mrrev.2021.108392","article-title":"A molecular genetics view on Mucopolysaccharidosis Type II","volume":"788","author":"Verma","year":"2021","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_32","first-page":"107","article-title":"Mucopolysaccharidosis type II, Hunter\u2019s syndrome","volume":"12","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/humu.1380020603","article-title":"Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate-2-sulphatase gene","volume":"2","author":"Hopwood","year":"1993","journal-title":"Hum. Mutat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.1189","article-title":"Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications","volume":"18","author":"Yogalingam","year":"2001","journal-title":"Hum. Mutat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/00005072-199710000-00010","article-title":"Human mucopolysaccharidosis IIID: Clinical, biochemical, morphological and immunohistochemical characteristics","volume":"56","author":"Jones","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_36","first-page":"89","article-title":"Mucopolysaccharidosis type VII: Characterization of mutations and molecular heterogeneity","volume":"48","author":"Tomatsu","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/humu.20828","article-title":"Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome)","volume":"30","author":"Tomatsu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(91)90512-W","article-title":"Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor","volume":"64","author":"Yayon","year":"1991","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1126\/science.1646484","article-title":"Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation","volume":"252","author":"Rapraeger","year":"1991","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.293.5535.1663","article-title":"Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase","volume":"293","author":"Dhoot","year":"2001","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbiotec.2007.01.022","article-title":"The heparanome\u2014The enigma of encoding and decoding heparan sulfate sulfation","volume":"129","author":"Lamanna","year":"2007","journal-title":"J. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","article-title":"Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding","volume":"14","author":"Capurro","year":"2008","journal-title":"Dev. Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.devcel.2008.03.001","article-title":"Cellular trafficking of the glypican Dally-like is required for full-strength Hedgehog signaling and wingless transcytosis","volume":"14","author":"Gallet","year":"2008","journal-title":"Dev. Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/dbio.2000.9831","article-title":"glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development","volume":"225","author":"Viviano","year":"2000","journal-title":"Dev. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.matbio.2005.07.008","article-title":"Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation","volume":"25","author":"Fisher","year":"2006","journal-title":"Matrix Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.devcel.2006.03.009","article-title":"Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis","volume":"10","author":"Jakobsson","year":"2006","journal-title":"Dev. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ydbio.2014.04.010","article-title":"Sulf1 influences the Shh morphogen gradient during the dorsal ventral patterning of the neural tube in Xenopus tropicalis","volume":"391","author":"Ramsbottom","year":"2014","journal-title":"Dev. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"a002493","DOI":"10.1101\/cshperspect.a002493","article-title":"Shaping morphogen gradients by proteoglycans","volume":"1","author":"Yan","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","article-title":"Functions of cell surface heparan sulfate proteoglycans","volume":"68","author":"Bernfield","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1126\/science.1090497","article-title":"Mammalian brain morphogenesis and midline axon guidance require heparan sulfate","volume":"302","author":"Inatani","year":"2003","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1242\/dev.01935","article-title":"Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function","volume":"132","author":"Grobe","year":"2005","journal-title":"Development"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ydbio.2013.10.014","article-title":"Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte maturation and skeletal length","volume":"385","author":"Mis","year":"2014","journal-title":"Dev. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bone.2011.02.001","article-title":"Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones","volume":"48","author":"Zak","year":"2011","journal-title":"Bone"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"19227","DOI":"10.1074\/jbc.M110.105338","article-title":"Conditional ablation of the heparan sulfate-synthesizing enzyme Ext1 leads to dysregulation of bone morphogenic protein signaling and severe skeletal defects","volume":"285","author":"Matsumoto","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1196\/annals.1402.063","article-title":"Synovial joint formation during mouse limb skeletogenesis: Roles of Indian hedgehog signaling","volume":"1116","author":"Koyama","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ydbio.2013.02.008","article-title":"Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: A mechanism likely deranged in Hereditary Multiple Exostoses","volume":"377","author":"Huegel","year":"2013","journal-title":"Dev. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bone.2013.08.012","article-title":"Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice","volume":"57","author":"Sgariglia","year":"2013","journal-title":"Bone"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajhg.2014.01.020","article-title":"XYLT1 mutations in Desbuquois dysplasia type 2","volume":"94","author":"Bui","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-013-1351-y","article-title":"The missing \u201clink\u201d: An autosomal recessive short stature syndrome caused by a hypofunctional XYLT1 mutation","volume":"133","author":"Schreml","year":"2014","journal-title":"Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ajhg.2015.04.017","article-title":"Homozygosity for frameshift mutations in XYLT2 result in a spondylo-ocular syndrome with bone fragility, cataracts, and hearing defects","volume":"96","author":"Munns","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/jbmr.2834","article-title":"Spondyloocular Syndrome: Novel Mutations in XYLT2 Gene and Expansion of the Phenotypic Spectrum","volume":"31","author":"Taylan","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1073\/pnas.87.4.1342","article-title":"A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: Galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome","volume":"87","author":"Quentin","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"28841","DOI":"10.1074\/jbc.274.41.28841","article-title":"Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene","volume":"274","author":"Okajima","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/ajmg.a.36128","article-title":"Redefining the progeroid form of Ehlers-Danlos syndrome: Report of the fourth patient with B4GALT7 deficiency and review of the literature","volume":"161A","author":"Guo","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ajhg.2013.04.016","article-title":"Defective initiation of glycosaminoglycan synthesis due to B3GALT6 mutations causes a pleiotropic Ehlers-Danlos-syndrome-like connective tissue disorder","volume":"92","author":"Malfait","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ajhg.2013.04.003","article-title":"Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause a spectrum of skeletal and connective tissue disorders","volume":"92","author":"Nakajima","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1093\/hmg\/ddy234","article-title":"Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers-Danlos syndrome","volume":"27","author":"Pang","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0304-4165(02)00402-6","article-title":"Hereditary multiple exostoses and heparan sulfate polymerization","volume":"1573","author":"Zak","year":"2002","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00003086-198902000-00026","article-title":"Multiple hereditary osteochondromata","volume":"239","author":"Peterson","year":"1989","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1073\/pnas.1102284108","article-title":"Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism","volume":"108","author":"Tornberg","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","first-page":"1125","article-title":"Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy","volume":"19","author":"Nishiguchi","year":"2013","journal-title":"Mol. Vis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0041-1724118","article-title":"Heparan Sulfate Proteoglycans in Diabetes","volume":"47","author":"Hiebert","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","article-title":"Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?","volume":"75","author":"Narajczyk","year":"2010","journal-title":"Med. Hypotheses"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/cbin.11275","article-title":"Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases","volume":"45","author":"Gaffke","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fecarotta, S., Tarallo, A., Damiano, C., Minopoli, N., and Parenti, G. (2020). Pathogenesis of Mucopolysaccharidoses, an Update. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072515"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hampe, C.S., Yund, B.D., Orchard, P.J., Lund, T.C., Wesley, J., and McIvor, R.S. (2021). Differences in MPS I and MPS II Disease Manifestations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157888"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: Lysosomal storage disorders: The cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cr.2013.168","article-title":"The machinery of macroautophagy","volume":"24","author":"Feng","year":"2014","journal-title":"Cell Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"jcs246322","DOI":"10.1242\/jcs.246322","article-title":"Microautophagy-distinct molecular mechanisms handle cargoes of many sizes","volume":"133","author":"Schuck","year":"2020","journal-title":"J. Cell Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4161\/auto.4144","article-title":"Chaperone-mediated autophagy","volume":"3","author":"Dice","year":"2007","journal-title":"Autophagy"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","article-title":"Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications","volume":"14","author":"Sipione","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1471-4159.1978.tb12388.x","article-title":"Neurochemistry of the mucopolysaccharidoses: Brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls","volume":"30","author":"Constantopoulos","year":"1978","journal-title":"J. Neurochem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1471-4159.1978.tb06245.x","article-title":"Neurochemistry of the mucopolysaccharidoses: Brain glycosaminoglycans, lipids and lysosomal enzymes in mucopolysaccharidosis type III B (alpha-N-acetylglucosaminidase deficiency)","volume":"31","author":"Constantopoulos","year":"1978","journal-title":"J. Neurochem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1471-4159.1980.tb11220.x","article-title":"Mucopolysaccharidosis types IH, IS, II, and IIIA: Glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues","volume":"34","author":"Constantopoulos","year":"1980","journal-title":"J. Neurochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/bj1520057","article-title":"Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro","volume":"152","author":"Avila","year":"1975","journal-title":"Biochem. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0304-4165(83)90225-8","article-title":"Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds","volume":"761","author":"Cantz","year":"1983","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/mgme.2000.3139","article-title":"Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID","volume":"72","author":"Liour","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcdb.2004.03.002","article-title":"Secondary accumulation of gangliosides in lysosomal storage disorders","volume":"15","author":"Walkley","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1046\/j.1471-4159.1994.62051852.x","article-title":"Growth of ectopic dendrites on cortical pyramidal neurons in neuronal storage diseases correlates with abnormal accumulation of GM2 ganglioside","volume":"62","author":"Siegel","year":"1994","journal-title":"J. Neurochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/sj.cdd.4401834","article-title":"Gangliosides as apoptotic signals in ER stress response","volume":"13","author":"Tessitore","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-981-15-0602-4_19","article-title":"Autophagy in Mitochondrial Quality Control","volume":"1206","author":"Wang","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.bbamcr.2006.04.002","article-title":"Mitochondrial dynamics and Ca2+ signaling","volume":"1763","author":"Szabadkai","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ajhg.2011.11.011","article-title":"Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation","volume":"89","author":"Mayr","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","article-title":"Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders","volume":"23","author":"Plotegher","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/brain\/awu355","article-title":"Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model","volume":"138","author":"Martins","year":"2015","journal-title":"Brain"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10545-017-0048-0","article-title":"Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases","volume":"40","author":"Saffari","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.169.3941.141","article-title":"Inborn errors of mucopolysaccharide metabolism","volume":"169","author":"Neufeld","year":"1970","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Parini, R., and Deodato, F. (2020). Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082975"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1210\/edrv-7-3-314","article-title":"Receptor-mediated peptide transport through the blood-brain barrier","volume":"7","author":"Pardridge","year":"1986","journal-title":"Endocr. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/0026-0495(87)90099-0","article-title":"Human blood-brain barrier transferrin receptor","volume":"36","author":"Pardridge","year":"1987","journal-title":"Metabolism"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0169-409X(00)00139-3","article-title":"Delivery of peptides and proteins through the blood-brain barrier","volume":"46","author":"Bickel","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/17425247.2014.952627","article-title":"Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody","volume":"12","author":"Pardridge","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Pardridge, W.M. (2022). A Historical Review of Brain Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061283"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ymthe.2021.01.027","article-title":"Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice","volume":"29","author":"Morimoto","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtm.2022.05.002","article-title":"Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice","volume":"25","author":"Morimoto","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.ymgmr.2021.100758","article-title":"Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II","volume":"27","author":"Yamamoto","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A Phase 2\/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil","volume":"29","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Sato, Y., and Okuyama, T. (2020). Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020400"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Giugliani, R., Martins, A.M., Okuyama, T., Eto, Y., Sakai, N., Nakamura, K., Morimoto, H., Minami, K., Yamamoto, T., and Yamaoka, M. (2021). Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci., 22.","DOI":"10.20944\/preprints202109.0192.v1"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Sonoda, H., Takahashi, K., Minami, K., Hirato, T., Yamamoto, T., So, S., Tanizawa, K., Schmidt, M., and Sato, Y. (2022). Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061240"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BPO.0b013e31821f5ee9","article-title":"Musculoskeletal manifestations of Sanfilippo Syndrome (mucopolysaccharidosis type III)","volume":"31","author":"White","year":"2011","journal-title":"J. Pediatr. Orthop."},{"key":"ref_116","unstructured":"Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (2022, September 29). Mucopolysaccharidosis Type III, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546574\/pdf\/Bookshelf_NBK546574.pdf."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","article-title":"Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: A retrospective case series analysis of nine sibships","volume":"10","author":"Bay","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jhg.2016.133","article-title":"Comparative study of idursulfase beta and idursulfase in vitro and in vivo","volume":"62","author":"Kim","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e145445","DOI":"10.1172\/jci.insight.145445","article-title":"Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome","volume":"6","author":"Arguello","year":"2021","journal-title":"JCI Insight"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e00617","DOI":"10.1002\/mgg3.617","article-title":"Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses","volume":"7","author":"Lin","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2408402","DOI":"10.1155\/2020\/2408402","article-title":"Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive\/Palliative Therapies","volume":"2020","author":"Nan","year":"2020","journal-title":"Biomed Res. Int."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.28.1","article-title":"Advances in the cell biology of transport via the inner blood-retinal barrier: Establishment of cell lines and transport functions","volume":"28","author":"Hosoya","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10545-005-0069-y","article-title":"Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses","volume":"28","author":"Tomatus","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-009-9036-3","article-title":"Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I","volume":"33","author":"Tomatsu","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2014.07.008","article-title":"Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses","volume":"113","author":"Shimada","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","article-title":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","volume":"125","author":"Tanaka","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"38305","DOI":"10.1038\/srep38305","article-title":"Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H","volume":"6","author":"Raymond","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4155\/bio.15.243","article-title":"A novel LC-MS\/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients","volume":"8","author":"Naimy","year":"2016","journal-title":"Bioanalysis"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): An open label phase 1-2 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpeds.2018.01.044","article-title":"Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B","volume":"197","author":"Whitley","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","article-title":"Intrathecal enzyme replacement for Hurler syndrome: Biomarker association with neurocognitive outcomes","volume":"21","author":"Eisengart","year":"2019","journal-title":"Genet. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ymgme.2019.05.005","article-title":"Evaluation of biomarkers for Sanfilippo syndrome","volume":"128","author":"Saville","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: Management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: A review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymgmr.2013.10.001","article-title":"Growth charts for patients with Hunter syndrome","volume":"1","author":"Patel","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ymgmr.2015.11.001","article-title":"Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment","volume":"5","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jmd2.12239","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpeds.2015.11.079","article-title":"A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA","volume":"170","author":"Shapiro","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: Results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-term outcomes of systemic therapies for Hurler syndrome: An international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2017.05.009","article-title":"Incomplete biomarker response in mucopolysaccharidosis type I after successful hematopoietic cell transplantation","volume":"122","author":"Kuiper","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome\u2014An expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1254\/fpj.21080","article-title":"Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO\u00ae I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)","volume":"157","author":"Yamamoto","year":"2022","journal-title":"Folia Pharmacol. Jpn."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2022.07.016","article-title":"Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2022.07.017","article-title":"Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2\/3 randomized study","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-8118-8-7","article-title":"Drug transport in brain via the cerebrospinal fluid","volume":"8","author":"Pardridge","year":"2011","journal-title":"Fluids Barriers CNS"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2012.05.005","article-title":"Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II","volume":"107","author":"Higuchi","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1038\/cddis.2013.430","article-title":"Murine neural stem cells model Hunter disease in vitro: Glial cell-mediated neurodegeneration as a possible mechanism involved","volume":"4","author":"Zalfa","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e2331","DOI":"10.1038\/cddis.2016.231","article-title":"Glial degeneration with oxidative damage drives neuronal demise in MPSII disease","volume":"7","author":"Zalfa","year":"2016","journal-title":"Cell Death Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:46:00Z","timestamp":1760143560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":154,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911724"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911724","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}